JP2010515882A - 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 - Google Patents
睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 Download PDFInfo
- Publication number
- JP2010515882A JP2010515882A JP2009544931A JP2009544931A JP2010515882A JP 2010515882 A JP2010515882 A JP 2010515882A JP 2009544931 A JP2009544931 A JP 2009544931A JP 2009544931 A JP2009544931 A JP 2009544931A JP 2010515882 A JP2010515882 A JP 2010515882A
- Authority
- JP
- Japan
- Prior art keywords
- sleep
- disorder
- disorders
- agonist
- promoting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000007958 sleep Effects 0.000 title claims abstract description 429
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 348
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title claims abstract description 109
- 229960003692 gamma aminobutyric acid Drugs 0.000 title claims abstract description 72
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 70
- 208000025966 Neurological disease Diseases 0.000 title claims abstract description 10
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title claims description 243
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title claims description 243
- 150000001875 compounds Chemical class 0.000 claims abstract description 473
- 208000035475 disorder Diseases 0.000 claims abstract description 347
- 208000019116 sleep disease Diseases 0.000 claims abstract description 330
- 230000001737 promoting effect Effects 0.000 claims abstract description 316
- 239000005557 antagonist Substances 0.000 claims abstract description 253
- 238000000034 method Methods 0.000 claims abstract description 213
- 206010041349 Somnolence Diseases 0.000 claims abstract description 203
- 208000032140 Sleepiness Diseases 0.000 claims abstract description 202
- 230000037321 sleepiness Effects 0.000 claims abstract description 201
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 199
- 206010062519 Poor quality sleep Diseases 0.000 claims abstract description 198
- 208000028017 Psychotic disease Diseases 0.000 claims abstract description 196
- 102100028628 Bombesin receptor subtype-3 Human genes 0.000 claims abstract description 179
- 108010063504 bombesin receptor subtype 3 Proteins 0.000 claims abstract description 179
- 206010010904 Convulsion Diseases 0.000 claims abstract description 170
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 150
- 239000000556 agonist Substances 0.000 claims abstract description 125
- 230000036461 convulsion Effects 0.000 claims abstract description 123
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 119
- 239000004031 partial agonist Substances 0.000 claims abstract description 66
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 43
- 206010022437 insomnia Diseases 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 28
- 201000003631 narcolepsy Diseases 0.000 claims abstract description 23
- 238000012216 screening Methods 0.000 claims abstract description 11
- 239000008177 pharmaceutical agent Substances 0.000 claims abstract description 5
- 229940125425 inverse agonist Drugs 0.000 claims description 207
- 208000020685 sleep-wake disease Diseases 0.000 claims description 129
- 206010027603 Migraine headaches Diseases 0.000 claims description 115
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 107
- 210000004027 cell Anatomy 0.000 claims description 101
- 208000028698 Cognitive impairment Diseases 0.000 claims description 96
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 81
- 201000000980 schizophrenia Diseases 0.000 claims description 66
- 241000124008 Mammalia Species 0.000 claims description 62
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 54
- 208000011580 syndromic disease Diseases 0.000 claims description 53
- 101000695054 Homo sapiens Bombesin receptor subtype-3 Proteins 0.000 claims description 46
- 102000005962 receptors Human genes 0.000 claims description 45
- 108020003175 receptors Proteins 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 38
- 206010012289 Dementia Diseases 0.000 claims description 36
- 239000003446 ligand Substances 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 26
- 206010027599 migraine Diseases 0.000 claims description 26
- 208000019906 panic disease Diseases 0.000 claims description 26
- 239000012528 membrane Substances 0.000 claims description 25
- 238000003752 polymerase chain reaction Methods 0.000 claims description 22
- 201000002859 sleep apnea Diseases 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 19
- 206010033664 Panic attack Diseases 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 19
- 230000001419 dependent effect Effects 0.000 claims description 19
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 19
- 208000024714 major depressive disease Diseases 0.000 claims description 19
- 208000003417 Central Sleep Apnea Diseases 0.000 claims description 18
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 18
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 claims description 18
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 18
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 18
- 210000003574 melanophore Anatomy 0.000 claims description 18
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 17
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 17
- 231100000331 toxic Toxicity 0.000 claims description 17
- 230000002588 toxic effect Effects 0.000 claims description 17
- 208000033923 irregular sleep wake type circadian rhythm sleep disease Diseases 0.000 claims description 15
- 206010015037 epilepsy Diseases 0.000 claims description 13
- 230000001430 anti-depressive effect Effects 0.000 claims description 10
- 230000000561 anti-psychotic effect Effects 0.000 claims description 10
- 239000000935 antidepressant agent Substances 0.000 claims description 10
- 229940005513 antidepressants Drugs 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 10
- 230000001773 anti-convulsant effect Effects 0.000 claims description 9
- 230000002460 anti-migrenic effect Effects 0.000 claims description 9
- 239000001961 anticonvulsive agent Substances 0.000 claims description 9
- 229960003965 antiepileptics Drugs 0.000 claims description 9
- 230000000949 anxiolytic effect Effects 0.000 claims description 9
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 8
- 208000015814 Intrinsic Sleep disease Diseases 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims description 7
- 201000005439 recurrent hypersomnia Diseases 0.000 claims description 7
- 229940125724 sleeping drug Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 230000037411 cognitive enhancing Effects 0.000 claims description 5
- 238000007596 consolidation process Methods 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 4
- 230000037410 cognitive enhancement Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 208000014486 central sleep apnea syndrome Diseases 0.000 claims 4
- 229940126062 Compound A Drugs 0.000 claims 1
- 229940080349 GPR agonist Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 238000003556 assay Methods 0.000 description 268
- 239000000126 substance Substances 0.000 description 56
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 229920001184 polypeptide Polymers 0.000 description 43
- 102000004196 processed proteins & peptides Human genes 0.000 description 43
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 37
- 230000027455 binding Effects 0.000 description 37
- 238000009739 binding Methods 0.000 description 37
- 239000000427 antigen Substances 0.000 description 30
- 108091007433 antigens Proteins 0.000 description 30
- 102000036639 antigens Human genes 0.000 description 30
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 26
- 241000894006 Bacteria Species 0.000 description 20
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 20
- 150000002632 lipids Chemical class 0.000 description 20
- 241000206602 Eukaryota Species 0.000 description 18
- 230000003834 intracellular effect Effects 0.000 description 18
- 208000000044 Amnesia Diseases 0.000 description 15
- 208000031091 Amnestic disease Diseases 0.000 description 15
- 230000006986 amnesia Effects 0.000 description 15
- 208000008811 Agoraphobia Diseases 0.000 description 14
- 239000006185 dispersion Substances 0.000 description 13
- 230000009885 systemic effect Effects 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 230000036506 anxiety Effects 0.000 description 11
- 239000000049 pigment Substances 0.000 description 11
- XOFLBQFBSOEHOG-UUOKFMHZSA-N γS-GTP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O XOFLBQFBSOEHOG-UUOKFMHZSA-N 0.000 description 11
- 108091006027 G proteins Proteins 0.000 description 10
- 102000030782 GTP binding Human genes 0.000 description 10
- 108091000058 GTP-Binding Proteins 0.000 description 10
- 108010043958 Peptoids Proteins 0.000 description 10
- 150000003384 small molecules Chemical class 0.000 description 10
- 206010010305 Confusional state Diseases 0.000 description 9
- SXDPQGRNHSLZPC-ZJNRKIDTSA-N CNC(=O)C[C@@H]1C[C@H]([C@@H](CN1)NC(=O)c1cc(c(Cl)o1)-c1c(Cl)cnn1C)c1ccc(F)c(F)c1 Chemical compound CNC(=O)C[C@@H]1C[C@H]([C@@H](CN1)NC(=O)c1cc(c(Cl)o1)-c1c(Cl)cnn1C)c1ccc(F)c(F)c1 SXDPQGRNHSLZPC-ZJNRKIDTSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 238000000159 protein binding assay Methods 0.000 description 8
- 208000017194 Affective disease Diseases 0.000 description 7
- 241000239290 Araneae Species 0.000 description 7
- 206010012239 Delusion Diseases 0.000 description 7
- 208000020401 Depressive disease Diseases 0.000 description 7
- 208000001495 Disorganized Schizophrenia Diseases 0.000 description 7
- 208000019022 Mood disease Diseases 0.000 description 7
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 7
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 description 7
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 7
- 206010034912 Phobia Diseases 0.000 description 7
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 7
- 208000029899 Sexual aversion disease Diseases 0.000 description 7
- 206010041250 Social phobia Diseases 0.000 description 7
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 7
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 7
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 7
- 208000026345 acute stress disease Diseases 0.000 description 7
- 231100000868 delusion Toxicity 0.000 description 7
- 208000024732 dysthymic disease Diseases 0.000 description 7
- 229910052738 indium Inorganic materials 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 208000028173 post-traumatic stress disease Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000000698 schizophrenic effect Effects 0.000 description 7
- 201000001716 specific phobia Diseases 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229940095074 cyclic amp Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 201000001441 melanoma Diseases 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 210000003796 lateral hypothalamic area Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010068871 Myotonic dystrophy Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 3
- 101710164423 Mitogen-activated protein kinase kinase kinase 1 Proteins 0.000 description 3
- 102000002512 Orexin Human genes 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 201000004810 Vascular dementia Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 150000001982 diacylglycerols Chemical class 0.000 description 3
- -1 diazepam Chemical class 0.000 description 3
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 108060005714 orexin Proteins 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 108010073466 Bombesin Receptors Proteins 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- QMCOPDWHWYSJSA-UHFFFAOYSA-N N-methyl-9H-pyrido[3,4-b]indole-3-carboxamide Chemical compound N1C2=CC=CC=C2C2=C1C=NC(C(=O)NC)=C2 QMCOPDWHWYSJSA-UHFFFAOYSA-N 0.000 description 2
- 102000052872 Neuromedin B receptors Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 210000001073 mediodorsal thalamic nucleus Anatomy 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000000955 prescription drug Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- QBYYXIDJOFZORM-LBPAWUGGSA-N 4-amino-5-chloro-n-[(3s,4r)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide;hydrate Chemical compound O.C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 QBYYXIDJOFZORM-LBPAWUGGSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108010066671 Enalaprilat Proteins 0.000 description 1
- 229940125633 GPCR agonist Drugs 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101000600779 Homo sapiens Neuromedin-B receptor Proteins 0.000 description 1
- 241001546602 Horismenus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 206010022995 Irregular sleep phase Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
- 101000695050 Mus musculus Bombesin receptor subtype-3 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- VMXUWOKSQNHOCA-UHFFFAOYSA-N N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine Chemical compound [O-][N+](=O)C=C(NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101000695052 Rattus norvegicus Bombesin receptor subtype-3 Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000007034 advanced sleep phase syndrome Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 229940098165 atrovent Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229940015273 buspar Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940072282 cardura Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- KEWHKYJURDBRMN-XSAPEOHZSA-M chembl2134724 Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-XSAPEOHZSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940097499 cozaar Drugs 0.000 description 1
- 229940075925 depakote Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229940072271 diprivan Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 229940090436 imitrex Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005127 montelukast Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940072273 pepcid Drugs 0.000 description 1
- 102000014187 peptide receptors Human genes 0.000 description 1
- 108010011903 peptide receptors Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 210000003814 preoptic area Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 229940108485 tenormin Drugs 0.000 description 1
- NZMOFYDMGFQZLS-UHFFFAOYSA-N terazosin hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 NZMOFYDMGFQZLS-UHFFFAOYSA-N 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940099270 vasotec Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229940070384 ventolin Drugs 0.000 description 1
- 229940009065 wellbutrin Drugs 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
- 229940108322 zantac Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87879607P | 2007-01-05 | 2007-01-05 | |
| PCT/US2008/000116 WO2008085888A1 (en) | 2007-01-05 | 2008-01-04 | G protein-coupled receptor and modulators thereof for the treatment of gaba-related neurological disorders including sleep-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010515882A true JP2010515882A (ja) | 2010-05-13 |
| JP2010515882A5 JP2010515882A5 (enExample) | 2012-03-08 |
Family
ID=39472025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544931A Withdrawn JP2010515882A (ja) | 2007-01-05 | 2008-01-04 | 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20110038850A1 (enExample) |
| EP (1) | EP2117577A1 (enExample) |
| JP (1) | JP2010515882A (enExample) |
| WO (1) | WO2008085888A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017511386A (ja) * | 2014-04-15 | 2017-04-20 | バランス セラピューティックス，インコーポレイテッド | 過眠症を治療するための方法 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| JP6500092B2 (ja) | 2014-09-15 | 2019-04-10 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物 |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149569A0 (en) * | 1999-11-17 | 2002-11-10 | Arena Pharm Inc | Endogenous and non-endogenous versions of human g protein-coupled receptors |
| WO2005011612A2 (en) * | 2003-07-31 | 2005-02-10 | The Research Foundation Of State University Of New York | Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| WO2005060625A2 (en) * | 2003-12-11 | 2005-07-07 | The Trustees Of Columbia University In The City Of New York | Grp receptor-related methods for treating and preventing fear-related disorders |
| GB0328796D0 (en) * | 2003-12-12 | 2004-01-14 | Biofocus Plc | Compounds which interact with the G-protein coupled receptor family |
| US8354241B2 (en) * | 2005-04-27 | 2013-01-15 | Arena Pharmaceuticals, Inc. | Methods for identifying a GLP-1 secretagogue |
-
2008
- 2008-01-04 US US12/521,274 patent/US20110038850A1/en not_active Abandoned
- 2008-01-04 EP EP08712989A patent/EP2117577A1/en not_active Withdrawn
- 2008-01-04 WO PCT/US2008/000116 patent/WO2008085888A1/en not_active Ceased
- 2008-01-04 JP JP2009544931A patent/JP2010515882A/ja not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017511386A (ja) * | 2014-04-15 | 2017-04-20 | バランス セラピューティックス，インコーポレイテッド | 過眠症を治療するための方法 |
| JP2020105200A (ja) * | 2014-04-15 | 2020-07-09 | バランス セラピューティックス，インコーポレイテッド | 過眠症を治療するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008085888A1 (en) | 2008-07-17 |
| US20110038850A1 (en) | 2011-02-17 |
| EP2117577A1 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515882A (ja) | 睡眠関連障害を含むｇａｂａ関連神経学的障害を処置するためのｇタンパク質共役受容体およびその調節因子 | |
| US7829298B2 (en) | Human G protein-coupled receptors for metabolic-related disorders | |
| JP5769361B2 (ja) | 高血糖症および関連障害の処置のための、ヒトｇタンパク質共役レセプターおよびそのモジュレーター | |
| US20140255310A1 (en) | Human G Protein-Coupled Receptor and Modulators Thereof for the Treatment of Atherosclerosis and Atherosclerotic Disease and for the Treatment of Conditions Related to MCP-1 Expression | |
| US20160077113A1 (en) | Methods of Identifying Candidate Compounds of the Human G Protein-Coupled Receptor, GPR50, as Modulators of Body Mass or Adiposity | |
| US8142762B2 (en) | Methods of using GPR101 receptors to identify modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion | |
| WO2005119252A2 (en) | Modulators of gpr35 for the treatment of metabolic-related disorders | |
| JP2011162567A (ja) | 心血管障害の処置のためのヒトｇタンパク質共役型レセプターおよびそのモジュレーター | |
| US20070231263A1 (en) | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110104 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110104 |
|
| A072 | Dismissal of procedure [no reply to invitation to correct request for examination] |
Free format text: JAPANESE INTERMEDIATE CODE: A073 Effective date: 20120508 |
|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20120605 |